Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of acapatamab in metastatic castration-resistant prostate cancer
jRCT2031200362Phase 1Completed
- Sponsor
- Amgen
- Start
- Feb 2019
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of acapatamab in metastatic castration-resistant prostate cancer (mCRPC) and prostate cancer (PCa) (7 arms), sponsored by Amgen. Primary endpoints: Number of participants with dose-limiting toxicity, Number of participants with treatment-emergent adverse events and 4 more. Started Feb 2019; status: completed.
02
Drugs
acapatamab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031200362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200362.